The tumor microenvironment significantly influences malignant behavior and progression. Many components are involved in the tumor microenvironment, including extracellular matrix, stromal cells, immune and inflammatory cells, as well as cytokines that promote tumor development with complex interactions through the exchange of molecular information. It is now known that tumor immune escape may be influenced by the tumor microenvironment. The aim of this work is to conduct a review of the tumor immune-microenvironment in gastric cancer.
Methods:
We review the current knowledge of several immune cells involved in the gastric tumor microenvironment. In addition, a brief description of immunotherapy strategies for gastric cancer is also reviewed.
Conclusions:
Among immune cell populations, lymphocytes, macrophages, dendritic cells and myeloid-derived suppressor cells are revealed to make the difference in promoting or suppressing gastric tumorigenesis, either directly or indirectly, via regulating the immune responses. Understanding these interactions in detail within the tumor immune-microenvironment will contribute to unraveling new therapeutic targets.
KarimiPIslamiFAnandasabapathyS, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-713.
2.
SeidlitzTKooBKStangeDE.Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine. Cell Death Differ. 2021;28:68-83.
3.
de MartelCFormanDPlummerM. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42:219-240.
4.
AlbertsSRCervantesAvan de VeldeCJ.Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14(S2):ii31-36.
5.
FerroAPeleteiroBMalvezziM, et al. Worldwide trendsin gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330-1344.
6.
RahmanRAsombangAWIbdahJA.Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014;20(16):4483-4490.
7.
SmythECNilssonMGrabschHI, et al. Gastric cancer. Lancet. 2020;396:635-648.
HatakeyamaM.Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(4):196-219.
10.
WangFMengWWangB, et al. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345(2):196-202.
11.
NasrRShamseddineAMukherjiD, et al. The crosstalk between microbiome and immune response in gastric cancer. Int J Mol Sci. 2020;21(18):6586.
12.
BoquetPRicciV.Intoxication strategy of Helicobacter pylori VacA toxin. Trends Microbiol. 2012;20:165-174.
13.
QuailDFJoyceJA.Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-1437.
14.
SammarcoGVarricchiGFerraroV, et al. Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer. Int J Mol Sci. 2019;20(9):2106.
15.
WangMLiZPengY, et al. Identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer. 2020;20:206.
16.
LinCHeHLiuH, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019;68(10):1764-1773.
17.
FanXJinJYanL, et al. The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer. Clin Immunol. 2020;219:108551.
18.
ChangWJDuYZhaoX, et al. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 2014;20:4586-4596.
19.
PernotSTermeMRadosevic-RobinN, et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer. 2020;23(1):73-81.
20.
LiQZhangDHeW, et al. CD8(+) T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. Oncol Lett. 2020;20:2655-2664.
21.
OyaYHayakawaYKoikeK.Tumor microenvironment in gastric cancers. Cancer Sci. 2020;111(8):2696-2707.
22.
WangJLiRCaoY, et al. Intratumoral CXCR5(+)CD8(+)T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. Nat Commun. 2021;12:3080.
23.
JinKCaoYGuY, et al. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. Oncoimmunology2021;10(1):1915560.
24.
ChochiKIchikuraTMajimaT, et al. The increase of CD57+ T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer. Oncol Rep. 2003;10:1443-1448.
25.
OuyangWRutzSCrellinNK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71-109.
26.
SmithLKBoukhaledGMCondottaSA, et al. Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity. 2018;48:299-312 e295.
27.
ZhongCSongZLiM.Gastric cancer patients display a distinctive population of IFNg(+)IL10(+) double positive CD8 T cells, which persists longer during prolonged activation. Exp Cell Res. 2019;382(2):111487.
28.
YuanZPengLZhaoY, et al. CD8+ T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology. 2012;143:951-962.e958.
29.
ZhuangHDaiXZhangX, et al. Sophoridine suppresses macrophage-mediated immunosuppression through TLR4/IRF3 pathway and subsequently upregulates CD8(+) T cytotoxic function against gastric cancer. Biomed Pharmacother. 2020;121:109636.
30.
GaoFGKhammanivongVLiuWJ, et al. Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell. Cancer Research. 2002;62:6438-6441.
31.
BergmanMPD’EliosMM. Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma. J Biomed Biotechnol. 2010;2010:104918.
32.
RomagnaniS.T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol. 2000;85(1):9-18; quiz 18, 21.
33.
BuhrmannCYazdiMPopperB, et al. Resveratrol chemosensitizes TNF-beta-induced survival of 5-fu-treated colorectal cancer cells. Nutrients2018;10(7):888.
34.
SallustoF.Heterogeneity of human CD4(+) T cells against microbes. Annu Rev Immunol. 2016;34:317-334.
35.
BaileyTStarkSGrantA, et al. A multidonor ELISPOT study of IL-1 beta, IL-2, IL-4, IL-6, IL-13, IFN-gamma and TNF-alpha release by cryopreserved human peripheral blood mononuclear cells. J Immunol Methods. 2002;270:171-182.
36.
KaimUMoritzAFailingK, et al. The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA. Immunology. 2006;118(4):472-482.
37.
ShiJWSongXJTraubB, et al. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021;22(6):2998.
38.
HallettMAVenmarKTFingletonB.Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 2012;72:6338-6343.
39.
SanguineteMMMOliveiraPHMartins-FilhoA, et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest. 2017;46:677-688.
40.
SuZLSunYKZhuHT, et al. Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis. Immunologic Research. 2014;58(1):118-124.
41.
GueryLHuguesS.Th17 cell plasticity and functions in cancer immunity. Biomed Res Int. 2015;2015:314620.
42.
ChangSH.T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res. 2019;42:549-559.
43.
YasudaKTakeuchiYHirotaK.The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41:283-297.
44.
MiossecPKollsJK.Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-776.
45.
WangLYiTSKortylewskiM, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206(7):1457-1464.
46.
KryczekIWeiSSzeligaW, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357-359.
47.
Martin-OrozcoNMuranskiPChungY, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787-798.
48.
IidaTIwahashiMKatsudaM, et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 2011;25:1271-1277.
49.
YamadaYSaitoHIkeguchiM.Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J Surg Res. 2012;178(2):685-691.
50.
RezalotfiAAhmadianEAazamiH, et al. Gastric cancer stem cells effect on Th17/Treg balance; a bench to beside perspective. Front Oncol. 2019;9:226.
51.
HiraharaNNioYSasakiS, et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology. 2001;61(1):79-89.
52.
MengXZhuSDongQ, et al. Expression of Th17/Treg related molecules in gastric cancer tissues. Turk J Gastroenterol. 2018;29:45-51.
53.
LiQChenJLiuY, et al. Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncol Rep. 2013;30:1215-1222.
54.
LiuTPengLYuP, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012;32:1332-1339.
55.
LiFSunYHuangJ, et al. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis. Cancer Med. 2019;8:7330-7344.
56.
KanamoriMNakatsukasaHOkadaM, et al. Induced regulatory T cells: their development, stability, and applications. Trends Immunol. 2016;37:803-811.
57.
SakaguchiSYamaguchiTNomuraT, et al. Regulatory T cells and immune tolerance. Cell. 2008;133:775-787.
58.
OhkuraNKitagawaYSakaguchiS.Development and maintenance of regulatory T cells. Immunity. 2013;38:414-423.
59.
KimJKKlingerMBenjaminJ, et al. Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking. PLoS One. 2009;4:e6580.
60.
OhkuraNSakaguchiS.Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases. Cell Res. 2020;30:465-474.
61.
PerroneGRuffiniPACatalanoV, et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008;44:1875-1882.
62.
SakaguchiSSakaguchiNShimizuJ, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
63.
HaasMDimmlerAHohenbergerW, et al. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009;9:65.
64.
DingTYanFCaoS, et al. Regulatory B cell: New member of immunosuppressive cell club. Hum Immunol. 2015;76:615-621.
65.
SarvariaAMadrigalJASaudemontA.B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14(8):662-674.
66.
ShenMSunQWangJ, et al. Positive and negative functions of B lymphocytes in tumors. Oncotarget. 2016;7:55828-55839.
67.
BalkwillFMontfortACapassoM.B regulatory cells in cancer. Trends Immunol. 2013;34:169-173.
68.
WangKLiuJLiJ.IL-35-producing B cells in gastric cancer patients. Medicine (Baltimore). 2018;97:e0710.
69.
JiangXChenYPengH, et al. Single line or parallel lines: NK cell differentiation driven by T-bet and Eomes. Cell Mol Immunol. 2012;9(3):193-194.
70.
HerbermanRBNunnMELavrinDH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16:216-229.
71.
KiesslingRKleinEWigzellH. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112-117.
72.
VivierETomaselloEBaratinM, et al. Functions of natural killer cells. Nat Immunol. 2008;9:503-510.
StetsonDBMohrsMReinhardtRL, et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med. 2003;198:1069-1076.
75.
WajantHPfizenmaierKScheurichP.Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45-65.
76.
AktasONOzturkABErmanB, et al. Role of natural killer cells in lung cancer. J Cancer Res Clin Oncol. 2018;144:997-1003.
77.
ZamaiLPontiCMirandolaP, et al. NK cells and cancer. J Immunol. 2007;178:4011-4016.
78.
ChengMChenYXiaoW, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230-252.
79.
ShimasakiNJainACampanaD.NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200-218.
80.
ChenJYangJJiangJ, et al. Function and subsets of dendritic cells and natural killer cells were decreased in gastric cancer. Int J Clin Exp Pathol. 2014;7:8304-8311.
81.
RautelaJSouza-Fonseca-GuimaraesFHediyeh-ZadehS, et al. Molecular insight into targeting the NK cell immune response to cancer. Immunol Cell Biol. 2018;96(5):477-484.
82.
LeeHSchlerethSLParkEY, et al. A novel pro-angiogenic function for interferon-gamma-secreting natural killer cells. Invest Ophthalmol Vis Sci. 2014;55:2885-2892.
83.
BassaniBBaciDGallazziM, et al. Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects. Cancers2019;11(4):461.
84.
BrunoAMortaraLBaciD, et al. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol. 2019;10:771.
85.
ChiossoneLDumasPYVienneM, et al. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671-688.
86.
VivierEArtisDColonnaM, et al. Innate Lymphoid Cells: 10 Years On. Cell. 2018;174:1054-1066.
87.
ArtisDSpitsH.The biology of innate lymphoid cells. Nature. 2015;517:293-301.
88.
FuchsAVermiWLeeJS, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity. 2013;38:769-781.
89.
BieQZhangPSuZ, et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res. 2014;2014:923135.
90.
LiRJiangXXZhangLF, et al. Group 2 innate lymphoid cells are involved in skewed type 2 immunity of gastric diseases induced by Helicobacter pylori infection. Mediators Inflamm. 2017;2017:4927964.
91.
BusadaJTPetersonKNKhadkaS, et al. Glucocorticoids and Androgens Protect From Gastric Metaplasia by Suppressing Group 2 Innate Lymphoid Cell Activation. Gastroenterol. 2021;161:637-652 e634.
92.
EbboMCrinierAVelyF, et al. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17:665-678.
93.
MantovaniASchioppaTPortaC, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315-322.
94.
SolinasGGermanoGMantovaniA, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukocyte Biol. 2009;86:1065-1073.
95.
GeissmannFManzMGJungS, et al. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327(5966):656-661.
96.
SalmiM.Macrophages and cancer. Duodecim. 2017;133:829-837.
97.
VarolCMildnerAJungS.Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33:643-675.
98.
NoyRPollardJW.Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49-61.
99.
HagemannTBiswasSKLawrenceT, et al. Regulation of macrophage function in tumors: the multifaceted role of NF-kappa B. Blood. 2009;113(14):3139-3146.
100.
GambardellaVCastilloJTarazonaN, et al. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev.2020;86:102015.
101.
HardbowerDMAsimMMurray-StewartT, et al. Arginase 2 deletion leads to enhanced M1 macrophage activation and upregulated polyamine metabolism in response to Helicobacter pylori infection. Amino Acids. 2016;48(10):2375-2388.
102.
LiuJYPengCWYangGF, et al. Distribution pattern of tumor associated macrophages predicts the prognosis of gastric cancer. Oncotarget. 2017;8:92757-92769.
103.
AlbertoM.Macrophages, neutrophils, and cancer: a double edged sword. New J Science. 2014; 2014(7):1-14.
104.
LeeKHwangHNamKT.Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. Gut & Liver. 2014;8(2):131-139.
105.
BiswasSKMantovaniA.Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 2010;11:889-896.
106.
YamaguchiTFushidaSYamamotoY, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2016;19:1052-1065.
107.
CollinMHaniffaM.Dendritic cells and dendritic cell subsets. Encycl Immunobiol. 2016;1:345-352.
108.
CoutantFMiossecP.Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles. Nat Rev Rheumatol. 2016;12:703-715.
109.
VegliaFGabrilovichDI.Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43-51.
110.
HuangXMLiuXSLinXK, et al. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Sci. 2014;105:150-158.
111.
LiuWJieZLiQ, et al. Gastric cancer patients have elevated plasmacytoid and CD1c+ dendritic cells in the peripheral blood. Oncology Letters2018;15(4):5087-5092.
112.
DemoulinSHerfsMDelvenneP, et al. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukocyte Biol. 2013;93:343-352.
113.
KalbMLGlaserAStaryG, et al. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J Immunol. 2012;188:1583-1591.
114.
TelJSmitsELAnguilleS, et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood. 2012;120(19):3936-3944.
115.
GabrilovichDIBronteVChenSH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425; author reply 426.
116.
SinhaPChornoguzOClementsVK, et al. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011;117:5381-5390.
117.
GabrilovichDINagarajS.Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
118.
UmanskyVAdemaGJBaranJ, et al. Interactions among myeloid regulatory cells in cancer. Cancer Immunol Immunother. 2019;68:645-660.
119.
LiNHanDSunJ, et al. Subtypes of MDSCs in mechanisms and prognosis of gastric cancer and are inhibited by epirubicin and paclitaxel. Discov Med. 2018;25:99-112.
120.
YounJINagarajSCollazoM, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791-5802.
121.
RodriguezPCOchoaAC.Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180-191.
122.
MesaliHAjamiAHussein-NattajH, et al. Regulatory T cells and myeloid-derived suppressor cells in patients with peptic ulcer and gastric cancer. Iran J Immunol. 2016;13(3):167-177.
123.
HsuHPWangCYHsiehPY, et al. Knockdown of serine/threonine-protein kinase 24 promotes tumorigenesis and myeloid-derived suppressor cell expansion in an orthotopic immunocompetent gastric cancer animal model. J Cancer2020; 11: 213-228.
124.
YonedaAKurokiTEguchiS.Immunotherapeutic advances in gastric cancer. Surg Today. 2021;51:1727-1735.
125.
SharmaPAllisonJP.Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205-214.
126.
FuchsCSOzgurogluMBangYJ, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. Epub ahead of print1September2021. DOI: 10.1007/s10120-021-01227-z.
127.
ShitaraKOzgurogluMBangYJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123-133.
128.
JanjigianYYMaronSBChatilaWK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:821-831.
129.
KangYKBokuNSatohT, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461-2471.
130.
SimpsonTRLiFMontalvo-OrtizW, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695-1710.
131.
YangLHWangYXWangHF.Use of immunotherapy in the treatment of gastric cancer. Oncol Lett. 2019;18(6):5681-5690.
132.
AjaniJAHechtJRHoL, et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006;106:1908-1916.
133.
SundarRRhaSYYamaueH, et al. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 2018;18(1):332.
134.
ZhangWLuXCuiPL, et al. Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immun. 2019;68:121-130.
135.
WangMLLuoYXSunT, et al. The Ectopic Expression of Survivin T34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer. Oncotargets Ther. 2020;13:1011-1025.
136.
FuchsCSDoiTJangRW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013.
137.
FerlayJEMLamFColombetM, et al. Global Cancer Observatory: Cancer Today, https://gco.iarc.fr/today (2020, accessed February 2021).
